Elemer Piros
Stock Analyst at EF Hutton
(2.13)
# 1,489
Out of 4,415 analysts
89
Total ratings
43.9%
Success rate
n/a
Average return
Main Sectors:
28 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HOTH Hoth Therapeutics | Maintains: Buy | $12 → $7.5 | $1.21 | +519.83% | 3 | Sep 14, 2023 | |
| COYA Coya Therapeutics | Reiterates: Buy | $28 | $8.78 | +218.91% | 6 | Aug 9, 2023 | |
| ATAI Atai Life Sciences | Reiterates: Buy | $15 | $2.05 | +631.71% | 8 | Aug 9, 2023 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Buy | $21 | $10.00 | +110.00% | 8 | Aug 4, 2023 | |
| CMPS COMPASS Pathways | Reiterates: Buy | $38 | $8.53 | +345.49% | 9 | Aug 3, 2023 | |
| KTTA Pasithea Therapeutics | Reiterates: Buy | $40 | $6.95 | +475.54% | 2 | Jul 10, 2023 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $5 | $1.12 | +346.43% | 5 | Jun 30, 2023 | |
| CYBN Cybin | Reiterates: Buy | $3 | $0.35 | +757.14% | 3 | Jun 20, 2023 | |
| CLNN Clene | Maintains: Buy | $13 → $10 | $0.43 | +2,199.38% | 6 | Jun 20, 2023 | |
| OPT Opthea | Reiterates: Buy | $23 | $3.32 | +592.77% | 2 | May 16, 2023 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $24 → $17 | $0.66 | +2,475.76% | 5 | Mar 28, 2023 | |
| GHRS GH Research | Reiterates: Buy | $33 | $11.68 | +182.53% | 3 | Mar 2, 2023 | |
| APLS Apellis Pharmaceuticals | Downgrades: Sell | $40 | $47.46 | -15.72% | 6 | Apr 14, 2022 | |
| UBX Unity Biotechnology | Upgrades: Buy | $40 | $1.61 | +2,384.47% | 3 | Jan 4, 2022 | |
| BRTX BioRestorative Therapies | Initiates: Buy | n/a | $1.37 | - | 1 | Dec 1, 2021 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | n/a | $3.00 | - | 2 | Jun 30, 2021 | |
| DRRX DURECT | Initiates: Buy | n/a | $1.16 | - | 1 | Oct 12, 2020 | |
| CWBR CohBar | Initiates: Buy | n/a | $0.80 | - | 1 | Sep 17, 2020 | |
| CRBP Corbus Pharmaceuticals Holdings | Downgrades: Neutral | n/a | $38.77 | - | 3 | Sep 8, 2020 | |
| ARCT Arcturus Therapeutics Holdings | Reinstates: Buy | n/a | $26.52 | - | 1 | Jul 30, 2020 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | n/a | $24.44 | - | 3 | Dec 17, 2018 | |
| KRYS Krystal Biotech | Initiates: Overweight | n/a | $161.10 | - | 1 | Sep 11, 2018 | |
| COOL Corner Growth Acquisition | Maintains: Overweight | n/a | $11.50 | - | 1 | Jun 13, 2018 | |
| DVAX Dynavax Technologies | Maintains: Overweight | n/a | $11.74 | - | 2 | Nov 10, 2017 | |
| ALDX Aldeyra Therapeutics | Initiates: Overweight | n/a | $4.21 | - | 1 | Oct 25, 2017 | |
| ABEO Abeona Therapeutics | Maintains: Overweight | n/a | $4.60 | - | 1 | Oct 12, 2017 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | n/a | $6.17 | - | 1 | Jul 12, 2017 | |
| OMER Omeros | Downgrades: Neutral | n/a | $3.72 | - | 1 | May 11, 2017 |
Hoth Therapeutics
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.21
Upside: +519.83%
Coya Therapeutics
Aug 9, 2023
Reiterates: Buy
Price Target: $28
Current: $8.78
Upside: +218.91%
Atai Life Sciences
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $2.05
Upside: +631.71%
Mind Medicine (MindMed)
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $10.00
Upside: +110.00%
COMPASS Pathways
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $8.53
Upside: +345.49%
Pasithea Therapeutics
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $6.95
Upside: +475.54%
Unicycive Therapeutics
Jun 30, 2023
Reiterates: Buy
Price Target: $5
Current: $1.12
Upside: +346.43%
Cybin
Jun 20, 2023
Reiterates: Buy
Price Target: $3
Current: $0.35
Upside: +757.14%
Clene
Jun 20, 2023
Maintains: Buy
Price Target: $13 → $10
Current: $0.43
Upside: +2,199.38%
Opthea
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.32
Upside: +592.77%
Monopar Therapeutics
Mar 28, 2023
Maintains: Buy
Price Target: $24 → $17
Current: $0.66
Upside: +2,475.76%
GH Research
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $11.68
Upside: +182.53%
Apellis Pharmaceuticals
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $47.46
Upside: -15.72%
Unity Biotechnology
Jan 4, 2022
Upgrades: Buy
Price Target: $40
Current: $1.61
Upside: +2,384.47%
BioRestorative Therapies
Dec 1, 2021
Initiates: Buy
Price Target: n/a
Current: $1.37
Upside: -
DiaMedica Therapeutics
Jun 30, 2021
Maintains: Buy
Price Target: n/a
Current: $3.00
Upside: -
DURECT
Oct 12, 2020
Initiates: Buy
Price Target: n/a
Current: $1.16
Upside: -
CohBar
Sep 17, 2020
Initiates: Buy
Price Target: n/a
Current: $0.80
Upside: -
Corbus Pharmaceuticals Holdings
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $38.77
Upside: -
Arcturus Therapeutics Holdings
Jul 30, 2020
Reinstates: Buy
Price Target: n/a
Current: $26.52
Upside: -
Arrowhead Pharmaceuticals
Dec 17, 2018
Maintains: Overweight
Price Target: n/a
Current: $24.44
Upside: -
Krystal Biotech
Sep 11, 2018
Initiates: Overweight
Price Target: n/a
Current: $161.10
Upside: -
Corner Growth Acquisition
Jun 13, 2018
Maintains: Overweight
Price Target: n/a
Current: $11.50
Upside: -
Dynavax Technologies
Nov 10, 2017
Maintains: Overweight
Price Target: n/a
Current: $11.74
Upside: -
Aldeyra Therapeutics
Oct 25, 2017
Initiates: Overweight
Price Target: n/a
Current: $4.21
Upside: -
Abeona Therapeutics
Oct 12, 2017
Maintains: Overweight
Price Target: n/a
Current: $4.60
Upside: -
Ocular Therapeutix
Jul 12, 2017
Maintains: Overweight
Price Target: n/a
Current: $6.17
Upside: -
Omeros
May 11, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.72
Upside: -